{"text": ["AbbVie", "Rises", "3.02%"], "created_at": "2018-09-13 20:38:03"}
{"text": ["Should", "Value", "Investors", "Consider", "AbbVie", "(ABBV)", "Stock", "Now?"], "created_at": "2018-09-13 15:49:39"}
{"text": ["Should", "Value", "Investors", "Consider", "AbbVie", "(ABBV)", "Stock", "Now?"], "created_at": "2018-09-13 15:49:39"}
{"text": ["AbbVie", "Inc.", "--", "Moody's", "assigns", "Baa2", "to", "AbbVie's", "sr.", "notes;", "stable", "outlook"], "created_at": "2018-09-13 14:46:05"}
{"text": ["Should", "Value", "Investors", "Consider", "AbbVie", "(ABBV)", "Stock", "Now?"], "created_at": "2018-09-13 13:30:01"}
{"text": ["AbbVie", "Presents", "Upadacitinib", "Longer-Term", "(32-Week)", "and", "Patient-Reported", "Outcomes", "Data", "from", "Phase", "2b", "Atopic", "Dermatitis", "Study", "at", "27th", "European", "Academy", "of", "Dermatology", "and", "Venereology", "(EADV)", "Congress"], "created_at": "2018-09-13 13:20:00"}
{"text": ["AbbVie", "Announces", "Patient-Reported", "Outcomes", "Data", "from", "Three", "Pivotal", "Phase", "3", "Studies", "of", "Risankizumab,", "Showing", "Significant", "Improvements", "in", "Health-Related", "Quality", "of", "Life", "for", "Patients", "with", "Psoriasis"], "created_at": "2018-09-13 10:20:00"}
